Pregnancy and Infant Outcomes After Prenatal Exposure to Golimumab in Denmark, Finland, and Sweden 2006-2019.

Pär Karlsson Karin Gembert Suzan Esslinger Anja Geldhof Gissler Mika Maarit K Leinonen Marijo Otero-Lobato Lars Pedersen Carolyn E Cesta

Published in: Pharmacoepidemiology and drug safety (2024)

The number of infants with prenatal golimumab exposure was low, but results are reassuringly consistent with the evidence available for other anti-TNF biologics. Continued monitoring is needed.

Keyphrases

pregnant women
ankylosing spondylitis
ulcerative colitis
rheumatoid arthritis
pregnancy outcomes
preterm birth